TumCG Cancer Research Results

TumCG, Tumor cell growth: Click to Expand ⟱
Source:
Type:
Normal cells grow and divide in a regulated manner through the cell cycle, which consists of phases (G1, S, G2, and M).
Cancer cells often bypass these regulatory mechanisms, leading to uncontrolled proliferation. This can result from mutations in genes that control the cell cycle, such as oncogenes (which promote cell division) and tumor suppressor genes (which inhibit cell division).
Scientific Papers found: Click to Expand⟱
4902- Sal,  OXA,    Salinomycin and oxaliplatin synergistically enhances cytotoxic effect on human colorectal cancer cells in vitro and in vivo
- vitro+vivo, CRC, NA
RadioS↑, ChemoSen↑, TumCP↓, Apoptosis↑, ROS↑, MMP↓, MAPK↑, eff↓, TumCG↓, TumCCA↑,
4903- Sal,    Salinomycin: A new paradigm in cancer therapy
- Review, Var, NA
TumCG↓, ATP↓, CSCs↓, ROS↑, Casp↑, MMP↓, selectivity↑, OXPHOS↓, STAT3↓, P53↑, γH2AX↑, cycD1/CCND1↓, TumCCA↑, DNAdam↑, ChemoSen↑,
4995- Sal,    Salinomycin possesses anti-tumor activity and inhibits breast cancer stem-like cells via an apoptosis-independent pathway
- vitro+vivo, BC, MDA-MB-231
ALDH↓, Nanog↓, OCT4↓, SOX2↓, CSCs↓, tumCV↓, cycD1/CCND1↓, P21↑, TumCG↓, CD44↓, Apoptosis∅,
4909- Sal,    Salinomycin: Anti-tumor activity in a pre-clinical colorectal cancer model
- vitro+vivo, CRC, NA
AntiTum↑, Apoptosis↑, mtDam↑, ROS↑, SOD1↓, ChemoSen↑, CSCs↑, ALDH↓, TumCG↓, TumCP↓, TumCD↑, ATP↓,
5123- Sal,    Salinomycin suppresses LRP6 expression and inhibits both Wnt/β-catenin and mTORC1 signaling in breast and prostate cancer cells
- in-vitro, BC, MCF7 - in-vitro, Pca, PC3 - in-vitro, Pca, DU145 - in-vitro, BC, MDA-MB-231 - in-vitro, Nor, HEK293
Wnt↓, β-catenin/ZEB1↓, mTORC1↓, GSK‐3β↑, cycD1/CCND1↓, survivin↓, LRP6↓, TumCG↓, Apoptosis↑,
5122- Sal,    Identification of selective inhibitors of cancer stem cells by high-throughput screening
- in-vivo, BC, SUM159 - NA, NA, 4T1
CSCs↓, TumCG↓, Diff↑, selectivity↑, CD44↓, CD24↓, TumVol↓,
6440- SAO,    Biological Properties of Sandalwood Oil and Microbial Synthesis of Its Major Sesquiterpenoids
- Review, Var, NA
AntiCan↑, *Bacteria↓, *antiOx↑, *Inflam↓, *ROS↓, AntiTum↑, TumCG↓, tumCV↓, β-catenin/ZEB1↓, TumCMig↓, chemoPv↑,
6441- SAO,    Sandalwood Album Oil as a Botanical Therapeutic in Dermatology
- Review, PSA, NA
*Inflam↓, *eff↑, *5LO↓, *DPPH↓, *hepatoP↑, *ROS↓, *PGE2↓, *IL1β↓, *IL17↓, *PDE4↓, *tyrosinase↓, *AntiFungal↑, angioG↓, TumCG↓, DNAdam↑, *Snail↑, *Twist↑, *Vim↑, *EMT↓, *toxicity↓,
6442- SAO,    Medicinal properties of alpha-santalol, a naturally occurring constituent of sandalwood oil: review
- Review, RCC, NA
AntiTum↑, Apoptosis↑, TumCCA↑, *Inflam↓, selectivity↑, tumCV↓, Casp8↓, Casp9↓, Casp6↓, Casp3↓, cl‑PARP↑, angioG↓, VEGFR2/KDR/Flk1↓, Akt↑, mTOR↓, TumCG↓, *GSTs↑, *antiOx↑, *ROS↓,
6443- SAO,    α-Santalol, a derivative of sandalwood oil, induces apoptosis in human prostate cancer cells by causing caspase-3 activation
- in-vitro, Pca, PC3
tumCV↓, Apoptosis↑, DNAdam↑, Casp3↑, cl‑PARP↑, TumCG↓,
6449- SAO,    Skin cancer chemoprevention by α-santalol
- Review, Melanoma, A431
*chemoPv↑, Apoptosis↑, Casp↑, MMP↓, Cyt‑c↑, TumCCA↑, TumCG↓,
6451- SAO,    α-Santalol functionalized chitosan nanoparticles as efficient inhibitors of polo-like kinase in triple negative breast cancer
- vitro+vivo, BC, MDA-MB-231
TumCP↓, selectivity↑, Bcl-2↓, PLK1↓, BAD↑, Casp↑, BAX↑, Dose↝, TumCG↓,
5044- SAS,    xCT inhibitor sulfasalazine depletes paclitaxel-resistant tumor cells through ferroptosis in uterine serous carcinoma
- in-vitro, Var, NA
xCT/SLC7A11↓, Ferroptosis↑, ROS↑, IL1↓, IL2↓, NF-kB↓, GSH↓, TumCG↓, ChemoSen↑,
5042- SAS,    xCT: A Critical Molecule That Links Cancer Metabolism to Redox Signaling
- Review, Var, NA
xCT/SLC7A11↓, GSH↓, TumCG↓, TumCI↓, ROS↑, RadioS↑, eff↓,
5041- SAS,  Cisplatin,    Xc− inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism
- in-vitro, CRC, NA
xCT/SLC7A11↓, Inflam↓, Apoptosis↓, GSH↓, ROS↑, TumCG↓, selectivity↑, eff↑, eff↓,
5039- SAS,    Regulatory network of ferroptosis and autophagy by targeting oxidative stress defense using sulfasalazine in triple-negative breast cancer
- vitro+vivo, BC, NA
xCT/SLC7A11↓, ROS↑, GSH↓, Ferroptosis↑, TumCG↓, toxicity↓, lipid-P↑,
5036- SAS,    Targeting xCT with sulfasalazine suppresses triple-negative breast cancer growth via inducing autophagy and coordinating cell cycle and proliferation
- vitro+vivo, BC, MDA-MB-231 - in-vitro, BC, MDA-MB-468
xCT/SLC7A11↓, GSH↓, OS↑, Myc↓, CDK1↓, CD44↓, eff↑, TumCG↓,
4486- Se,  Chit,    Selenium-Modified Chitosan Induces HepG2 Cell Apoptosis and Differential Protein Analysis
- in-vitro, Liver, HepG2
Apoptosis↑, TumCCA↑, MMP↓, Bcl-2↓, BAX↑, cl‑Casp9↑, cl‑Casp3↑, Risk↓, *BioAv↑, *toxicity↑, TumCG↓, AntiTum↑, ROS↑, Cyt‑c↑, Fas↑, FasL↑, FADD↑,
4734- SeNPs,  CPT-11,    Cytotoxicity and therapeutic effect of irinotecan combined with selenium nanoparticles
- in-vitro, CRC, HCT8 - in-vivo, NA, NA
chemoP↑, ChemoSen↑, P53↑, Apoptosis↑, TumCG↓, Casp↑, Dose↝, NRF2↓, selectivity↑, *NRF2↑,
4469- SeNPs,    Selenium Nanoparticles in Cancer Therapy: Unveiling Cytotoxic Mechanisms and Therapeutic Potential
- Review, Var, NA
antiOx↑, selectivity↑, eff↑, AntiCan↑, Apoptosis↑, ROS↑, MMP↓, Casp3↑, Casp9↑, AntiTum↑, TumCG↓, TumMeta↓, angioG↓, Cyt‑c↑, DNAdam↑, RadioS↑, BBB↑, *toxicity↓, ChemoSen↑,
3193- SFN,    Epigenetic Therapeutics Targeting NRF2/KEAP1 Signaling in Cancer Oxidative Stress
- Review, Var, NA
DNMTs↓, HDAC↑, NRF2↑, DNMT1↓, DNMT3A↓, NQO1↑, COMT↑, TumCG↓, *toxicity↓,
110- SFN,    Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway
- in-vivo, PC, NA
HH↓, Smo↓, Gli1↓, GLI2↓, Shh↓, VEGF↓, PDGFRA↓, EMT↓, Zeb1↓, Bcl-2↓, XIAP↓, E-cadherin↑, OCT4↓, Nanog↓, TumCG↑,
2552- SFN,  Chemo,    Chemopreventive activity of sulforaphane
- Review, Var, NA
chemoPv↑, TumCG↓, *ROS↓, *Inflam↓, *Dose↝, *NRF2↑, *HO-1↑, *NQO1↑, NF-kB↓, ROS↑,
2448- SFN,    Sulforaphane and bladder cancer: a potential novel antitumor compound
- Review, Bladder, NA
Apoptosis↑, TumCG↓, TumCI↓, TumMeta↓, glucoNG↓, ChemoSen↑, TumCCA↑, Casp3↑, Casp7↑, cl‑PARP↑, survivin↓, EGFR↓, HER2/EBBR2↓, ATP↓, Glycolysis↓, mt-OXPHOS↓, AKT1↓, HK2↓, Hif1a↓, ROS↑, NRF2↑, EMT↓, COX2/PTGS2↓, MMP2↓, MMP9↓, Zeb1↓, Snail↓, HDAC↓, HATs↓, MMP↓, Cyt‑c↓, Shh↓, Smo↓, Gli1↓, BioAv↝, BioAv↝, Dose↝,
1469- SFN,    Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vivo, Pca, NA
eff↑, ROS↑, MMP↓, Casp3↑, Casp9↑, DR4↑, DR5↑, BAX↑, Bak↑, BIM↑, NOXA↑, Bcl-2↓, Bcl-xL↓, Mcl-1↓, eff↓, TumCG↓, TumCP↓, eff↑, NF-kB↓, PI3K↓, Akt↓, MEK↓, ERK↓, angioG↓, FOXO3↑,
1466- SFN,    Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway
- vitro+vivo, Thyroid, FTC-133
TumCP↓, TumCCA↑, Apoptosis↑, TumCMig↓, TumCI↓, EMT↓, Slug↓, Twist↓, MMP2↓, MMP9↓, TumCG↓, p‑Akt↓, P21↑, ERK↑, p38↑, ROS↑, *toxicity∅, MMP↓, eff↓,
1453- SFN,    Sulforaphane Reduces Prostate Cancer Cell Growth and Proliferation In Vitro by Modulating the Cdk-Cyclin Axis and Expression of the CD44 Variants 4, 5, and 7
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
TumCG↓, TumCP↓, TumCCA↑, H3↑, H4↑, HDAC↓, CDK1↑, CDK2↑, p19↑, *BioAv↑,
1434- SFN,  GEM,    Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity
- in-vitro, CCA, HuCCT1 - in-vitro, CCA, HuH28 - in-vivo, NA, NA
HDAC↓, ac‑H3↑, ChemoSen↑, tumCV↓, TumCP↓, TumCCA↑, Apoptosis↑, cl‑Casp3↑, TumCI↓, VEGF↓, VEGFR2/KDR/Flk1↓, Hif1a↓, eNOS↓, EMT?, TumCG↓, Ki-67↓, TUNEL↑, P21↑, p‑Chk2↑, CDC25↓, BAX↑, *ROS↓, NQO1?,
1474- SFN,    Sulforaphane induces p53‑deficient SW480 cell apoptosis via the ROS‑MAPK signaling pathway
- in-vitro, Colon, SW480
TumCG↓, Apoptosis↑, MMP↓, Bax:Bcl2↑, Casp3↑, Casp7↑, Casp9↑, ROS↑, e-ERK↑, p38↑, P53∅, eff↓, ChemoSen↑,
1507- SFN,    Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects
- in-vivo, Colon, NA - Human, Nor, NA
TumCG↓, HDAC↓, *BioAv↑, Dose∅, Half-Life∅,
1484- SFN,    Sulforaphane’s Multifaceted Potential: From Neuroprotection to Anticancer Action
- Review, Var, NA - Review, AD, NA
neuroP↑, AntiCan↑, NRF2↑, HDAC↓, eff↑, *ROS↓, neuroP↑, HDAC↓, *toxicity∅, BioAv↑, eff↓, cycD1/CCND1↓, CDK4↓, p‑RB1↓, Glycolysis↓, miR-30a-5p↑, TumCCA↑, TumCG↓, TumMeta↓, eff↑, ChemoSen↑, RadioS↑, CardioT↓, angioG↓, Hif1a↓, VEGF↓, *BioAv?, *Half-Life∅,
1736- SFN,    Antitumor and antimetastatic effects of dietary sulforaphane in a triple-negative breast cancer models
- in-vitro, BC, NA - in-vivo, BC, NA
TumCG↓, selectivity↓,
3301- SIL,    Critical review of therapeutic potential of silymarin in cancer: A bioactive polyphenolic flavonoid
- Review, Var, NA
Inflam↓, TumCCA↑, Apoptosis↓, TumMeta↓, TumCG↓, angioG↓, chemoP↑, radioP↑, p‑ERK↓, p‑p38↓, p‑JNK↓, P53↑, Bcl-2↓, Bcl-xL↓, TGF-β↓, MMP2↓, MMP9↓, E-cadherin↑, Wnt↓, Vim↓, VEGF↓, IL6↓, STAT3↓, *ROS↓, IL1β↓, PGE2↓, CDK1↓, CycB/CCNB1↓, survivin↓, Mcl-1↓, Casp3↑, Casp9↑, cMyc↓, COX2/PTGS2↓, Hif1a↓, CXCR4↓, CSCs↓, EMT↓, N-cadherin↓, PCNA↓, cycD1/CCND1↓, ROS↑, eff↑, eff↑, eff↑, HER2/EBBR2↓,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27/CDKN1B↑, COX2/PTGS2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1/SREBF1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
3648- SIL,    Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
- Review, NA, NA
*antiOx↑, *Inflam↓, *lipid-P↓, *necrosis↓, *hepatoP↑, *IL1↓, *IL6↓, *TNF-α↓, *IFN-γ↓, MAPK↓, Apoptosis↑, Cyt‑c↑, Casp3↑, Casp9↑, *PPARγ↑, *GLUT4↑, *HSPs↓, *HSP27↑, *Trx↑, *SIRT1↑, *ALAT↓, *GSH↑, *lipid-P↓, *TNF-α↓, TumCG↓, P21↑, CDK4↑,
109- SIL,    Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinoma
- vitro+vivo, RCC, 769-P - in-vitro, RCC, 786-O - in-vitro, RCC, ACHN - in-vitro, RCC, OS-RC-2
HH↓, Gli1↓, GLI2↓, mTOR↓, Bcl-2↓, Apoptosis↑, Casp3↑, PARP↑, TumCG↓,
1140- SIL,    Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth
- in-vitro, PC, AsPC-1 - in-vivo, PC, NA - in-vitro, PC, MIA PaCa-2 - in-vitro, PC, PANC1 - in-vitro, PC, Bxpc-3
TumCG↓, Glycolysis↓, cMyc↓, STAT3↓, TumCP↓, Weight∅, Strength↑, DNAdam↑, Casp3↑, Casp9↑, GLUT1↓, HK2↓, LDHA↓, GlucoseCon↓, lactateProd↓, PPP↓, Ki-67↓, p‑STAT3↓, cachexia↓,
1001- SIL,    Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism
- in-vitro, NA, NA
TumCG↓, Glycolysis↓, OXPHOS↑, LDHA↓, lactateProd↓, i-citrate↑, Hif1a↓, PD-L1↓,
2410- SIL,    Autophagy activated by silibinin contributes to glioma cell death via induction of oxidative stress-mediated BNIP3-dependent nuclear translocation of AIF
- in-vitro, GBM, U87MG - in-vitro, GBM, U251 - in-vivo, NA, NA
TumAuto↑, ATP↓, Glycolysis↓, H2O2↑, P53↑, GSH↓, xCT/SLC7A11↓, BNIP3↝, MMP↑, mt-ROS↑, mtDam↑, HK2↓, PFKP↓, PKM2↓, TumCG↓,
2359- SK,    Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery
- in-vivo, Liver, NA
TumCG↓, PKM2↓, EMT↓, TGF-β↓, Glycolysis↓, lactateProd↓, ATP↓,
2356- SK,    ESM1 enhances fatty acid synthesis and vascular mimicry in ovarian cancer by utilizing the PKM2-dependent warburg effect within the hypoxic tumor microenvironment
- in-vitro, Ovarian, CaOV3 - in-vitro, Ovarian, OV90 - in-vivo, NA, NA
PKM2↓, Glycolysis↓, FASN↓, lactateProd↓, Warburg↓, TumCG↓, VM↓,
2357- SK,    GTPBP4 promotes hepatocellular carcinoma progression and metastasis via the PKM2 dependent glucose metabolism
- Study, HCC, NA - in-vivo, NA, NA
AntiTum↑, GTPBP4↓, PKM2↓, lactateProd↓, GlucoseCon↓, Glycolysis↓, E-cadherin↑, TumCG↓,
2230- SK,    Shikonin induces ROS-based mitochondria-mediated apoptosis in colon cancer
- in-vitro, CRC, HCT116 - in-vivo, NA, NA
TumCG↓, Bcl-2↓, ROS↑, Bcl-xL↓, MMP↓, Casp↑, selectivity↑, cycD1/CCND1↓, TumCCA↑, eff↓,
2228- SK,    Shikonin induced Apoptosis Mediated by Endoplasmic Reticulum Stress in Colorectal Cancer Cells
- in-vitro, CRC, HCT116 - in-vitro, CRC, HCT15 - in-vivo, NA, NA
Apoptosis↑, Bcl-2↓, Casp3↑, Casp9↑, cl‑PARP↑, GRP78/BiP↑, PERK↑, eIF2α↑, ATF4↑, CHOP/DDIT3↑, JNK↑, eff↓, ER Stress↑, ROS↑, TumCG↓,
2219- SK,    Shikonin induces apoptosis of HaCaT cells via the mitochondrial, Erk and Akt pathways
- in-vitro, Nor, HaCaT
*MMP↓, *ROS↑, *Casp3↑, *TumCG↓,
2212- SK,    Shikonin Exerts an Antileukemia Effect against FLT3-ITD Mutated Acute Myeloid Leukemia Cells via Targeting FLT3 and Its Downstream Pathways
- in-vitro, AML, NA
FLT3↓, NF-kB↓, miR-155↓, Diff↑, TumCG↓,
3047- SK,    Shikonin suppresses colon cancer cell growth and exerts synergistic effects by regulating ADAM17 and the IL-6/STAT3 signaling pathway
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW48
TumCG↓, p‑STAT3↓, ADAM17↓, Apoptosis↑, Casp3↑, cl‑PARP↑, cycD1/CCND1↓, cycE/CCNE↓, TumCCA↑, JAK1?, p‑JAK1↓, p‑JAK2↓, p‑eIF2α↑, eff↓, ROS↑, IL6↓,
977- SK,    A novel antiestrogen agent Shikonin inhibits estrogen-dependent gene transcription in human breast cancer cells
- in-vitro, BC, T47D - in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF7 - in-vitro, Nor, HMEC
TumCG↓, ERα/ESR1↓, selectivity↑, *toxicity↓,
2009- SK,    Necroptosis inhibits autophagy by regulating the formation of RIP3/p62/Keap1 complex in shikonin-induced ROS dependent cell death of human bladder cancer
- in-vitro, Bladder, NA
TumCG↓, selectivity↑, *toxicity∅, Necroptosis↑, ROS↑, p62↑, Keap1↑, *NRF2↑, eff↑,
1343- SK,    Simple ROS-responsive micelles loaded Shikonin for efficient ovarian cancer targeting therapy by disrupting intracellular redox homeostasis
- in-vitro, Ovarian, A2780S - in-vivo, NA, A2780S
*BioAv↓, ROS↑, GSH↓, TumCG↓,

Showing Research Papers: 751 to 800 of 858
Prev Page 16 of 18 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 858

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Ferroptosis↑, 2,   GSH↓, 7,   H2O2↑, 1,   Keap1↑, 1,   lipid-P↑, 1,   NQO1?, 1,   NQO1↑, 1,   NRF2↓, 1,   NRF2↑, 3,   OXPHOS↓, 1,   OXPHOS↑, 1,   mt-OXPHOS↓, 1,   ROS↓, 1,   ROS↑, 20,   mt-ROS↑, 1,   SOD1↓, 1,   xCT/SLC7A11↓, 6,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 6,   CDC25↓, 1,   MEK↓, 1,   MMP↓, 11,   MMP↑, 1,   mtDam↑, 2,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AKT1↓, 1,   i-citrate↑, 1,   cMyc↓, 2,   FASN↓, 1,   glucoNG↓, 1,   GlucoseCon↓, 2,   Glycolysis↓, 8,   HK2↓, 3,   lactateProd↓, 5,   LDHA↓, 2,   PFKP↓, 1,   PKM2↓, 4,   PPP↓, 1,   SIRT1↓, 1,   SREBP1/SREBF1↓, 1,   Warburg↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   Akt↑, 1,   p‑Akt↓, 1,   Apoptosis↓, 2,   Apoptosis↑, 17,   Apoptosis∅, 1,   BAD↑, 1,   Bak↑, 1,   BAX↑, 4,   Bax:Bcl2↑, 1,   Bcl-2↓, 8,   Bcl-xL↓, 3,   BIM↑, 1,   Casp↑, 6,   Casp3↓, 1,   Casp3↑, 11,   cl‑Casp3↑, 2,   Casp6↓, 1,   Casp7↑, 2,   Casp8↓, 1,   Casp9↓, 1,   Casp9↑, 7,   cl‑Casp9↑, 1,   p‑Chk2↑, 1,   Cyt‑c↓, 1,   Cyt‑c↑, 5,   DR4↑, 1,   DR5↑, 1,   FADD↑, 1,   Fas↑, 1,   FasL↑, 1,   Ferroptosis↑, 2,   JNK↑, 1,   p‑JNK↓, 1,   MAPK↓, 1,   MAPK↑, 1,   Mcl-1↓, 2,   Myc↓, 1,   Necroptosis↑, 1,   NOXA↑, 1,   p27/CDKN1B↑, 1,   p38↑, 2,   p‑p38↓, 1,   survivin↓, 3,   Telomerase↓, 1,   TumCD↑, 1,   TUNEL↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

HER2/EBBR2↓, 2,  

Transcription & Epigenetics(tgid=7) ⓘ

H3↑, 1,   ac‑H3↑, 1,   H4↑, 1,   HATs↓, 1,   HATs↑, 1,   miR-30a-5p↑, 1,   tumCV↓, 5,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   eIF2α↑, 1,   p‑eIF2α↑, 1,   ER Stress↑, 1,   GRP78/BiP↑, 1,   PERK↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

BNIP3↝, 1,   p62↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 5,   DNMT1↓, 1,   DNMT3A↓, 1,   DNMTs↓, 1,   P53↑, 4,   P53∅, 1,   PARP↑, 1,   cl‑PARP↑, 5,   PCNA↓, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 2,   CDK1↑, 1,   CDK2↑, 1,   CDK4↓, 2,   CDK4↑, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 7,   cycE/CCNE↓, 1,   p19↑, 1,   P21↑, 5,   PLK1↓, 1,   p‑RB1↓, 1,   TumCCA↑, 14,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 2,   CD24↓, 1,   CD44↓, 4,   CSCs↓, 4,   CSCs↑, 1,   Diff↑, 2,   EMT?, 1,   EMT↓, 6,   ERK↓, 2,   ERK↑, 1,   p‑ERK↓, 1,   e-ERK↑, 1,   FLT3↓, 1,   FOXO3↑, 1,   Gli1↓, 3,   GSK‐3β↑, 1,   GTPBP4↓, 1,   HDAC↓, 7,   HDAC↑, 1,   HH↓, 2,   IGFBP3↑, 1,   LRP6↓, 1,   mTOR↓, 2,   mTORC1↓, 1,   Nanog↓, 2,   NOTCH↓, 1,   OCT4↓, 2,   PDGFRA↓, 1,   PI3K↓, 1,   Shh↓, 2,   Smo↓, 2,   SOX2↓, 1,   STAT3↓, 4,   p‑STAT3↓, 2,   TumCG↓, 48,   TumCG↑, 1,   Wnt↓, 3,  

Migration(tgid=13) ⓘ

CA↓, 1,   Ca+2↑, 1,   E-cadherin↑, 4,   FAK↓, 1,   GLI2↓, 2,   Ki-67↓, 2,   miR-155↓, 1,   miR-203↑, 1,   MMP2↓, 4,   MMP9↓, 4,   N-cadherin↓, 1,   PDGF↓, 1,   Slug↓, 1,   Snail↓, 1,   TGF-β↓, 3,   TumCI↓, 4,   TumCMig↓, 3,   TumCP↓, 8,   TumMeta↓, 4,   Twist↓, 1,   uPA↓, 1,   Vim↓, 2,   Zeb1↓, 3,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 7,   ATF4↑, 1,   EGFR↓, 2,   eNOS↓, 1,   Hif1a↓, 6,   VEGF↓, 6,   VEGFR2/KDR/Flk1↓, 2,   VM↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,   GLUT1↓, 1,   NHE1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 3,   CXCR4↓, 1,   IL1↓, 2,   IL1β↓, 1,   IL2↓, 1,   IL6↓, 2,   Inflam↓, 2,   JAK1?, 1,   p‑JAK1↓, 1,   p‑JAK2↓, 1,   NF-kB↓, 5,   PD-L1↓, 2,   PGE2↓, 2,   PSA↓, 1,  

Cellular Microenvironment(tgid=17) ⓘ

ADAM17↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,   COMT↑, 1,   ERα/ESR1↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 3,   BioAv↑, 1,   BioAv↝, 2,   ChemoSen↑, 10,   Dose↝, 4,   Dose∅, 1,   eff↓, 10,   eff↑, 11,   eff↝, 1,   Half-Life↓, 1,   Half-Life↝, 1,   Half-Life∅, 1,   RadioS↑, 4,   selectivity↓, 1,   selectivity↑, 11,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 1,   EGFR↓, 2,   ERα/ESR1↓, 1,   HER2/EBBR2↓, 2,   IL6↓, 2,   Ki-67↓, 2,   Myc↓, 1,   PD-L1↓, 2,   PSA↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 4,   AntiTum↑, 6,   cachexia↓, 1,   cardioP↑, 1,   CardioT↓, 1,   chemoP↑, 3,   chemoPv↑, 2,   hepatoP↑, 1,   neuroP↑, 2,   OS↑, 1,   radioP↑, 1,   Risk↓, 1,   Strength↑, 1,   toxicity↓, 1,   toxicity↝, 1,   toxicity∅, 1,   TumVol↓, 1,   Weight∅, 1,  
Total Targets: 260

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 4,   DPPH↓, 1,   GSH↑, 1,   GSTs↑, 1,   HO-1↑, 1,   lipid-P↓, 2,   NQO1↑, 1,   NRF2↑, 3,   ROS↓, 7,   ROS↑, 1,   Trx↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

MMP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   PPARγ↑, 1,   SIRT1↑, 2,  

Cell Death(tgid=5) ⓘ

Casp3↑, 1,   necrosis↓, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSP27↑, 1,   HSPs↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EMT↓, 1,   TumCG↓, 1,   tyrosinase↓, 1,  

Migration(tgid=13) ⓘ

5LO↓, 1,   Snail↑, 1,   TIMP1↓, 1,   Twist↑, 1,   Vim↑, 1,  

Barriers & Transport(tgid=15) ⓘ

GLUT4↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IFN-γ↓, 1,   IL1↓, 1,   IL17↓, 1,   IL1β↓, 1,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 6,   PGE2↓, 1,   TNF-α↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv?, 1,   BioAv↓, 1,   BioAv↑, 3,   Dose↝, 1,   eff↑, 1,   Half-Life∅, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

chemoPv↑, 1,   hepatoP↑, 2,   PDE4↓, 1,   toxicity↓, 4,   toxicity↑, 1,   toxicity∅, 3,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 1,   Bacteria↓, 1,  
Total Targets: 53

Scientific Paper Hit Count for: TumCG, Tumor cell growth
29 Curcumin
27 Magnetic Fields
17 Phenethyl isothiocyanate
16 Quercetin
14 Berberine
14 EGCG (Epigallocatechin Gallate)
14 Sulforaphane (mainly Broccoli)
13 Silver-NanoParticles
13 Chemotherapy
13 Shikonin
12 Vitamin C (Ascorbic Acid)
12 Magnetic Field Rotating
12 Bicarbonate(Sodium)
11 Alpha-Lipoic-Acid
11 Baicalein
11 Garcinol
11 IP6 (Inositol 1,2,3,4,5,6-hexakisphosphate)
10 Capsaicin
10 Apigenin (mainly Parsley)
10 chaetocin
10 Fisetin
9 Cucurbitacin
9 Resveratrol
9 Silymarin (Milk Thistle) silibinin
9 Dichloroacetate
9 Deguelin
9 Formononetin
8 Astragalus
8 Radiotherapy/Radiation
8 Artemisinin
8 salinomycin
8 diet FMD Fasting Mimicking Diet
8 Emodin
8 Gambogic Acid
8 Ginkgetin
8 Honokiol
8 Ivermectin
8 Phenylbutyrate
8 Pterostilbene
8 Urolithin
7 Allicin (mainly Garlic)
7 HydroxyCitric Acid
7 Ashwagandha(Withaferin A)
7 immunotherapy
7 Boron
7 Boswellia (frankincense)
7 Crocetin
6 Metformin
6 Cisplatin
6 Betulinic acid
6 Chrysin
6 Coenzyme Q10
6 Gemcitabine (Gemzar)
6 diet Methionine-Restricted Diet
6 Sulfasalazine
6 Isoliquiritigenin
6 Magnolol
6 Indole-3-carbinol
6 Inulin Prebiotic
6 itraconazole
6 Juglone
6 Lycopene
6 Magnesium
6 Rosmarinic acid
6 α-Santalol/Sandalwood oil
5 chitosan
5 Melatonin
5 Berbamine
5 Beta-Caryophyllene
5 Centella asiatica / Gotu kola → asiaticoside
5 Citric Acid
5 Dandelion Root
5 Eugenol
5 Gallic acid
5 Graviola
5 isoquercitrin
4 3-bromopyruvate
4 Fenbendazole
4 doxorubicin
4 Paclitaxel/Taxol
4 Astaxanthin
4 Atorvastatin
4 Dipyridamole
4 Brucea javanica
4 Butyrate
4 Caffeic Acid Phenethyl Ester (CAPE)
4 Cynaropicrin
4 Docosahexaenoic Acid
4 Disulfiram
4 Evodiamine
4 Genistein (soy isoflavone)
4 Hydrogen Gas
4 Hyperoside
4 Isobavachalcone
4 Luteolin
4 Nimbolide
4 Piperine
4 Piperlongumine
4 Selenite (Sodium)
4 Thymoquinone
4 Vitamin K2
4 VitK3,menadione
3 Caffeic acid
3 Diclofenac
3 Baicalin
3 Bufalin/Huachansu
3 brusatol
3 Bruteridin(bergamot juice)
3 Carvacrol
3 Celastrol
3 Chlorogenic acid
3 Selenium NanoParticles
3 Copper and Cu NanoParticles
3 Photodynamic Therapy
3 tamoxifen
3 Ellagic acid
3 eicosapentaenoic acid
3 Fucoidan
3 Geraniol
3 Ginger/6-Shogaol/Gingerol
3 Glabrescione B
3 Gossypol/AT-101
3 HydroxyTyrosol
3 Inositol
3 Lemongrass Extract/Citral
3 Niclosamide (Niclocide)
3 Propyl gallate
3 Plumbagin
3 Terpinen-4-ol / Tea Tree Oil
3 Aflavin-3,3′-digallate
2 2-DeoxyGlucose
2 Auranofin
2 Phyllanthus emblica/Emblica officinalis/Amla / Indian Gooseberry
2 Andrographis
2 Anethole/trans-Anethole
2 Fennel Oil/Foeniculum vulgare
2 Ascorbyl Palmitate
2 Biochanin A
2 Bifidobacterium
2 Bromelain
2 α-Bisabolol / Chamomile oil
2 Carnosic acid
2 Cinnamon
2 Cynara scolymus/Globe Artichoke/Artichoke Extract
2 Polyphenols
2 Cyclopamine
2 Oxygen, Hyperbaric
2 diet Short Term Fasting
2 D-limonene
2 Ginkgo biloba-EGb 761
2 ferumoxytol
2 Galloflavin
2 Ginkgo biloba
2 Ginkgolide B
2 Grapeseed extract
2 Hydroxycinnamic-acid
2 iodine
2 metronomic chemo
2 Isovitexin
2 Kaempferol
2 Licochalcone A
2 Licorice
2 Linalool
2 Methylene blue
2 Oroxylin-A
2 Oleuropein
2 Orlistat
2 Psoralidin
2 Hyperthermia
2 EMF
2 Oxaliplatin
2 Spermidine
2 Ursolic acid
2 Vitexin
2 Whole Body Vibration
1 1,8-Cineole
1 5-fluorouracil
1 Anzaroot, Astragalus fasciculifolius Bioss
1 octreotide
1 Acetyl-l-carnitine
1 DTS(dibenzyl trisulphide) from Anamu
1 Angelica archangelica / Garden Angelica
1 Anti-oxidants
1 5-Aminolevulinic acid
1 Aloe anthraquinones
1 beta-glucans
1 temozolomide
1 Bacopa monnieri
1 Bullatacin
1 Caffeine
1 urea
1 Cat’s Claw
1 Cannabidiol
1 Celecoxib
1 Chocolate
1 Calorie Restriction Mimetics
1 Carvone
1 Bicalutamide
1 CUSP9
1 Dichloroacetophenone(2,2-)
1 Dasatinib/Phyrago
1 Bortezomib
1 Date Fruit Extract
1 diet Ketogenic
1 diet Plant based
1 Aspirin
1 Zinc
1 Echinacea
1 PXD, phenoxodiol
1 Sorafenib (brand name Nexavar)
1 Electrical Pulses
1 erastin
1 Eurycomanone
1 Shilajit/Fulvic Acid
1 Ginkgolic acids
1 Hibiscus sabdariffa
1 Lactobacillus
1 probiotics
1 Laetrile B17 Amygdalin
1 Lapachol
1 Lasiodin
1 Lactoferrin/Talactoferrin
1 mebendazole
1 Methylglyoxal
1 Mushroom Chaga
1 Naringin
1 Noscapine
1 Parthenolide
1 raloxifen
1 Salvia officinalis
1 Vorinostat
1 Selenium
1 irinotecan
1 Salvia miltiorrhiza
1 Saikosaponin B1 and D
1 Sutherlandioside D
1 cetuximab
1 Taurine
1 Tomatine
1 triptolide
1 Tumor Treating Fields
1 Turmerones
1 Usnic acid
1 Vitamin B1/Thiamine
1 Vitamin B5,Pantothenic Acid
1 Transarterial Chemoembolization
1 γ-Tocotrienol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:323  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page